Sintx Technologies (NASDAQ:SINT – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.02), FiscalAI reports. Sintx Technologies had a negative return on equity of 366.49% and a negative net margin of 1,058.60%.The business had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.46 million.
Here are the key takeaways from Sintx Technologies’ conference call:
- Revenue and margins improved substantially: Second-quarter revenue rose 199% year over year to $452,000, while product revenue increased 347% and gross margin expanded to 61.5% from 37.7%. Management cautioned that the gains came from a small base and margins may vary by product mix and manufacturing efficiency.
- SINTX reported purchase orders exceeding $3.2 million from existing contract-manufacturing customers, with production and shipments beginning and expected to continue into 2027. The company emphasized that converting these orders into recognized revenue will depend on production, quality release, shipment timing, customer acceptance, and cash collection.
- The SINAPTIC Foot and Ankle Osteotomy Wedge System generated initial commercial revenue after its first U.S. clinical use, but broader adoption remains dependent on surgeon education, distribution, product availability, reimbursement considerations, and market development.
- Liquidity remains a major risk: SINTX ended the quarter with $3.6 million in cash, used $5.3 million in operating cash during the first half, and disclosed substantial doubt about its ability to continue as a going concern. Management expects to pursue additional equity and/or debt financing despite approximately $5.1 million of remaining ATM capacity.
- The company continues to operate at a loss, with a second-quarter net loss of $2.7 million and first-half net loss of $5.5 million, while operating expenses increased 16% year over year. Management is evaluating staffing, facilities, outside services, inventory, and other costs as it works to align spending with commercial returns.
Sintx Technologies Price Performance
Shares of SINT stock traded down $0.16 during mid-day trading on Wednesday, hitting $1.61. The stock had a trading volume of 95,898 shares, compared to its average volume of 64,572. The firm has a market cap of $6.94 million, a PE ratio of -0.31 and a beta of 0.62. Sintx Technologies has a fifty-two week low of $1.40 and a fifty-two week high of $6.78. The company’s 50-day simple moving average is $1.82 and its 200-day simple moving average is $2.38.
Institutional Trading of Sintx Technologies
Analyst Ratings Changes
Several research analysts have commented on SINT shares. Maxim Group reaffirmed a “buy” rating and set a $6.00 price target on shares of Sintx Technologies in a research report on Thursday, June 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Sintx Technologies in a research report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Sintx Technologies in a report on Wednesday, May 20th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.
Check Out Our Latest Research Report on Sintx Technologies
Sintx Technologies Company Profile
Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.
The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.
Read More
- Five stocks we like better than Sintx Technologies
- Tesla’s Robotaxi Reality Check: Time to Deliver
- Hims & Hers’ Revenue Beat Came With a Profitability Problem
- A Westinghouse IPO Could Reset the Nuclear Stock Conversation
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
Receive News & Ratings for Sintx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sintx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
